An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Arcturus Therapeutics to Attend Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) will participate in several upcoming investor conferences, including Citi's 18th Annual BioPharma Conference, Wells Fargo Health Conference, H.C. Wainwright 25th Annual Global Investment Conference, Baird Global Healthcare Conference, Cantor Fitzgerald Global Healthcare Conference, and Chardan's 7th Annual Genetic Medicines Conference. Webcast links can be found on Arcturus' website.
Positive
None.
Negative
None.
SAN DIEGO--(BUSINESS WIRE)--
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences:
Webcast links can be found under Investor Relations/Events section of Arcturus’ website.
About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (samRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. The Company has ongoing collaborations with CSL Seqirus and Meiji Seika Pharma, and a joint venture with ARCALIS. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase deficiency and cystic fibrosis, along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.
IR and Media Contacts
Arcturus Therapeutics
Neda Safarzadeh
VP, Head of IR/PR/Marketing
(858) 900-2682
IR@ArcturusRx.com
Kendall Investor Relations
Carlo Tanzi, Ph.D.
(617) 914-0008
ctanzi@kendallir.com
Source: Arcturus Therapeutics
FAQ
What is the company name participating in the investor conferences?
The company participating in the investor conferences is Arcturus Therapeutics Holdings Inc.
What is the stock symbol of Arcturus Therapeutics Holdings Inc.?
The stock symbol of Arcturus Therapeutics Holdings Inc. is ARCT.
Which conferences will Arcturus Therapeutics Holdings Inc. participate in?
Arcturus Therapeutics Holdings Inc. will participate in Citi's 18th Annual BioPharma Conference, Wells Fargo Health Conference, H.C. Wainwright 25th Annual Global Investment Conference, Baird Global Healthcare Conference, Cantor Fitzgerald Global Healthcare Conference, and Chardan's 7th Annual Genetic Medicines Conference.
Where can I find the webcast links for the conferences?
The webcast links can be found under the Investor Relations/Events section of Arcturus' website.
